Supplementary Figure S8 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Key Points
Key points are not available for this paper at this time.
Abstract
Supplementary Figure S8 details the antitumor effects associated with coadministration of MRTX0902 and adagrasib in the MIA PaCa-2 (KRAS G12C-mutant) model.
Supplementary Figure S8 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading | Synapse
Also Consider
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
2Supplementary Figure S3 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading2024